Research Analysts’ Recent Ratings Updates for MacroGenics (MGNX)

Several analysts have recently updated their ratings and price targets for MacroGenics (NASDAQ: MGNX):

  • 1/11/2018 – MacroGenics was downgraded by analysts at BidaskClub from a “sell” rating to a “strong sell” rating.
  • 1/11/2018 – MacroGenics was upgraded by analysts at Zacks Investment Research from a “sell” rating to a “hold” rating. According to Zacks, “MacroGenics Inc. is a biopharmaceutical company. It is focused on discovering and developing innovative monoclonal antibody-based therapeutics. The Company has a diverse portfolio of product candidates focused in three therapeutic areas: oncology, autoimmune disorders and infectious diseases. MacroGenics Inc. is headquartered in Rockville, Maryland. “
  • 1/5/2018 – MacroGenics was upgraded by analysts at BidaskClub from a “strong sell” rating to a “sell” rating.
  • 1/3/2018 – MacroGenics was downgraded by analysts at Zacks Investment Research from a “hold” rating to a “sell” rating. According to Zacks, “MacroGenics Inc. is a biopharmaceutical company. It is focused on discovering and developing innovative monoclonal antibody-based therapeutics. The Company has a diverse portfolio of product candidates focused in three therapeutic areas: oncology, autoimmune disorders and infectious diseases. MacroGenics Inc. is headquartered in Rockville, Maryland. “
  • 12/14/2017 – MacroGenics was downgraded by analysts at BidaskClub from a “sell” rating to a “strong sell” rating.
  • 12/11/2017 – MacroGenics had its “buy” rating reaffirmed by analysts at Raymond James Financial, Inc..
  • 12/1/2017 – MacroGenics was upgraded by analysts at ValuEngine from a “strong sell” rating to a “sell” rating.

MacroGenics Inc (MGNX) traded up $0.30 during midday trading on Monday, hitting $19.19. 259,900 shares of the company were exchanged, compared to its average volume of 196,500. The stock has a market cap of $706.63, a P/E ratio of -4.27 and a beta of 2.73. MacroGenics Inc has a 1 year low of $14.36 and a 1 year high of $22.31.

MacroGenics (NASDAQ:MGNX) last posted its earnings results on Wednesday, November 8th. The biopharmaceutical company reported ($1.28) EPS for the quarter, missing the Zacks’ consensus estimate of ($1.09) by ($0.19). The company had revenue of $1.70 million during the quarter, compared to analysts’ expectations of $5.50 million. MacroGenics had a negative net margin of 1,526.55% and a negative return on equity of 69.31%. The company’s quarterly revenue was down 48.5% on a year-over-year basis. During the same period last year, the business earned ($0.97) earnings per share. analysts expect that MacroGenics Inc will post -0.7 earnings per share for the current year.

In related news, SVP Jon Marc Wigginton sold 5,000 shares of the stock in a transaction on Tuesday, November 21st. The shares were sold at an average price of $20.00, for a total value of $100,000.00. Following the transaction, the senior vice president now directly owns 35,000 shares of the company’s stock, valued at approximately $700,000. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Insiders sold a total of 20,000 shares of company stock worth $400,000 over the last ninety days. Insiders own 8.30% of the company’s stock.

MacroGenics, Inc is a clinical-stage biopharmaceutical company focused on discovering and developing monoclonal antibody-based therapeutics for the treatment of cancer, as well as various autoimmune disorders and infectious diseases. The Company develops therapeutic product candidates using its antibody-based technology platforms and also in collaboration with other biopharmaceutical companies.

Receive News & Ratings for MacroGenics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MacroGenics Inc and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply